P2.04-25 Randomized Clinical Trial Comparing Immunotherapy Plus SABR (I-Sabr) Versus SABR Alone for Early Stage NSCLC

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1249
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Phase I Trial: SABR and Ipilimumab—Letter

Clinical Cancer Research
Cancer ResearchOncology
2017English

SABR Combats Metastatic Disease

Cancer Discovery
Oncology
2018English

Population-Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for Up to 5 Oligometastases: SABR-5

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

P2.16-16 SABRTOOTH: A Fasibility Study of SABR Versus Surgery in Patients With Peripheral Stage I NSCLC Considered to Be at Higher Risk for Surgery

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MS20.02 the Future of Stereotactic Ablative Radiotherapy (SABR)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Imaging Follow-Up After Stereotactic Ablative Radiotherapy (SABR) for Lung Tumors

Journal of Radiation Oncology
OncologyRadiologyNuclear MedicineImaging
2012English

P2.16-14 Results of Stereotactic Radiation Therapy (SABR) in Early Stage Lung Cancer: Turkish Radiation Oncology Group (TROG) Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Optimizing SABR Delivery for Synchronous Multiple Lung Tumors Using Volumetric-Modulated Arc Therapy

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2017English

Assessment of Dose Distributions According to Low Magnetic Field Effect for Prostate SABR

Journal of Radiation Protection and Research
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy